



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## Revision of Precautions Sunitinib malate

September 18, 2018

## Non-proprietary name

Sunitinib malate

## Safety measure

Precautions should be revised in the package insert.

The following language should be added to the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section (revised language is underlined):

## Acute cholecystitis:

Acute cholecystitis, including acalculous cholecystitis, may occur. Patients should be carefully monitored, and if any abnormalities are observed, appropriate measures such as suspension of administration should be taken.